Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer

NCT03455907 | Completed

• 2 other identifiers: 2017_502017-A03012-51
• Study Type: observational
• Target: 71
• Locations: 1 country
• Sites: 2

Brief Summary

Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers. The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Conditions

Arthralgia

Keywords

Bevacizumab

Outcome Measures

Primary Outcomes (1)

• Frequency of arthralgia

  Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.

  At 6 months

Secondary Outcomes (2)

• correlation between global cancer response and occurrence of arthralgia

  baseline, at 3 months, at 6 months

• auto questionnaire specific to the study

  Baseline at 3 months, at 6 months

Study Arms (1)

Patients

patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated with Bevacizumab for Lung, ovarian or colorectal cancers.

You may qualify if:

• Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
• Male or female (aged ≥18 years old)
• Performance Status (PS) between 0 and 2
• Expected life\> 3 months
• Ability to answer a self-questionnaire
• Obtaining the non-opposition of patient participation

You may not qualify if:

• Pregnant or lactating woman
• Rapid evolution of neoplastic pathology
• Major cognitive disorders that do not allow filling of the self-questionnaire
• Impossibility to submit to medical monitoring for social, psychological or geographical reasons
• Patients under guardianship or curatorship

Sponsors & Collaborators

• University Hospital, Lille: lead

Study Sites (2)

Centre Oscar Lambret

Lille, France

Location

Hôpital Huriez. CHRU

Lille, France

Location

Related Publications (1)

• Vauleon E, Behal H, Lebellec L, Desbarbieux R, Baldacci S, Simon N, Pannier D, Vieillard MH, Turpin A. Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study. Cancer Chemother Pharmacol. 2021 Apr;87(4):533-541. doi: 10.1007/s00280-020-04226-6. Epub 2021 Jan 12.

  PMID: 33438069 RESULT

MeSH Terms

Conditions

Arthralgia

Condition Hierarchy (Ancestors)

Joint Diseases; Musculoskeletal Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Marie-Hélène Viellard, MD

  University Hospital, Lille

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2018
• First Posted: March 7, 2018
• Study Start: January 3, 2018
• Primary Completion: January 31, 2019
• Study Completion: January 31, 2019
• Last Updated: May 5, 2026

Record last verified: 2026-04

Locations

FR (2)